Zaltrap is an angiogenesis inhibitor that inhibits the blood supply to tumors. It is intended for patients with metastatic cancer and whose tumors are resistant to or progressed after an oxaliplatin-containing chemotherapy regimen.
“This approval demonstrates the benefits of adding a biological agent, Zaltrap, to a commonly used chemotherapy drug regimen, FOLFIRI,” said Richard Pazdur, MD, director of the Office of Hematology and Oncology Products in the FDA’s Center for Drug Evaluation and Research, in the release. “An improvement in median survival time was noted with the addition of Zaltrap to FOLFIRI, accompanied by an improvement in response rate and a delay in tumor progression and growth.”
Zaltrap is manufactured by Bridgewater, N.J.-based sanofi-aventis.
Related Articles on Colorectal Cancer:
Gastroenterologist on the Move: Dr. Raghu Dharmavaram Kottam Joins DE’s Bayhealth Milford
Study: Colonoscopy Significantly Reduces Colorectal Cancer
New Online Program Designed to Identify, Help Manage Genetic Risk for Colorectal Cancer
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
